Prenetics Global Ltd
(NAS:PRENW)
$
0.019
(0%)
Market Cap: 0
Enterprise Value: 0
PE Ratio: 0
PB Ratio: 4.16
GF Score: 73/100 
Q2 2026 Prenetics Global Ltd Earnings Call Transcript
Aug 18, 2026 / 12:30PM GMT
Release Date Price:
$0.0195
Key Points
Positve
- Prenetics Global Ltd (PRE) achieved its first month of positive consolidated adjusted free cash flow in July 2026, crossing a key profitability milestone ahead of schedule.
- The company delivered its sixth consecutive record quarter, with Q2 2026 revenue of $46.5 million, up 29% sequentially and 3.9x year-over-year, beating its own guidance.
- Customer acquisition costs (CAC) fell 21% in July to $239, even as the company acquired a record 47,373 new customers, demonstrating improving marketing efficiency.
- Prenetics Global Ltd (PRE) raised its full-year 2026 revenue guidance to $220-$230 million and initiated 2027 guidance of $400 million or more, driven by a strong recurring revenue base.
- The company secured a $1 billion funding commitment from General Catalyst, which will fund 70% of its acquisition marketing spend, removing a major cash constraint on growth.
- Prenetics Global Ltd (PRE) is expanding its product pipeline with IM8 Hydration and premium gummies, targeting large markets ($37 billion and $25 billion respectively), backed by ongoing clinical trials including one at the Mayo Clinic.
- The company's AI-native organizational structure allows it to scale efficiently, with revenue per employee exceeding $3 million and fixed operating costs falling 21% quarter-over-quarter.
- Independent data shows Prenetics Global Ltd (PRE) has superior customer retention (14.2% at month 20) compared to competitors like AG1 and Thorne, and it is gaining significant market share.
- The company maintains a strong balance sheet with $109.4 million in cash and current financial assets, and has reduced its share count through a $40 million buyback.
- Prenetics Global Ltd (PRE) is expanding its board with the addition of veteran consumer analyst Caroline Levy, adding significant industry expertise and credibility.
Negative
- Prenetics Global Ltd (PRE) reported a net loss of $9 million for Q2 2026, and while improving, the company is still not profitable on a GAAP basis.
- The company's adjusted EBITDA remained negative at -$19 million for Q2 2026, reflecting heavy investment in customer acquisition that has yet to fully pay off.
- The company's guidance for 2027 of $400 million or more is ambitious and relies on continued rapid growth, which may be difficult to sustain as the base becomes larger.
- Prenetics Global Ltd (PRE) faces intense competition in the supplement space from established brands like AG1, Thorne, and others, which could pressure market share and pricing.
- The company's growth is heavily dependent on a single product line (IM8 Daily Essentials), and the success of new product launches (hydration, gummies) is not yet proven.
- The company's customer acquisition costs, while improving, remain high at $239 per customer, and the long-term payback period for these investments is still being validated.
- Prenetics Global Ltd (PRE) is not currently in large markets like China and India, limiting its total addressable market in the near term.
- The company's reliance on the General Catalyst funding facility introduces financial risk, as the terms and repayment obligations could impact future cash flows.
- The company's stock price is volatile, and the potential dilution from warrants (2.36 million at $18 strike) could pressure shareholder value if the stock price rises.
- The company's expansion into new product categories and geographies will require significant investment and execution, which could strain its AI-native, lean organizational structure.
Operator
Actual results may differ materially. Please refer to the company's filings with the SEC. Certain figures for July are preliminary and unaudited. The full Q2 2026 shareholder letter and this investor presentation were published this morning and are available at ir.prenetics.com.
With that, it is my pleasure to hand the call over to Prenetics CEO, Danny.
Daany Yeung
Prenetics Global Ltd - Chairman of the Board, Chief Executive Officer, Co-Founder
Thank you, Shannon. Good morning, everyone. Before anything else, thank you so much for being here. This is actually the first live earnings video webcast we have done in our company's history. And from the numbers that are joining right now, it may be the largest group of our shareholders ever gathered in one place. So whether you manage a fund, hold a single share, or are simply here because you drink the sachet every morning, welcome. This is for you.
And here is why we are doing it this way. Our shareholders range from global institutions to people who found IM8 as customers and became
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers